MedicarePartD.guide

A non-government resource built from CMS public data

TNF blockers on every 2026 California Part D plan

Pick a drug class, or type the drugs you want to check, and see which of the 12 stand-alone Part D plans in California cover each one, on what tier, and with what restrictions.

A class overrides typed names. Separate names with commas; brand or generic both work.

  • Covered
  • Covered, needs prior authorization (PA) or step therapy (ST)
  • Not on the formulary
  • QL 60/30d = quantity limit, 60 units per 30 days

12 plans, cheapest premium first. Scroll sideways for all of them →

TNF blockers by 2026 California Part D plan
DrugHealthSpring Assurance Rx$0.00/moS5617-158Wellcare Value Script$5.70/moS4802-163Wellcare Classic$6.20/moS4802-094HealthSpring Extra Rx$70.60/moS5617-382SilverScript Choice$103.60/moS5601-064Humana Value Rx Plan$104.60/moS5884-211AARP Medicare Rx Saver from UHC$109.40/moS5921-376Humana Basic Rx Plan$132.20/moS5884-114AARP Medicare Rx Preferred from UHC$165.40/moS5921-413Humana Premier Rx Plan$172.90/moS5884-178Blue Shield Rx Plus$199.70/moS2468-003Blue Shield Rx Enhanced$227.80/moS2468-004
HumiraadalimumabNot coveredNot coveredNot coveredNot coveredTier 5PA25%QL 52/365dNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot covered
adalimumab biosimilarsadalimumab-adaz, -fkjp, -aacf and othersNot coveredTier 5PA25%QL 4/28dTier 5PA25%QL 4/28dNot coveredNot coveredTier 5PA26%QL 0.2/28dTier 5PA25%Tier 5PA25%QL 0.2/28dTier 5PA31%Tier 5PA33%QL 0.2/28dNot coveredNot covered
Hadlimaadalimumab-bwwdTier 5PA25%QL 2.4/28dNot coveredNot coveredTier 5PA25%QL 2.4/28dTier 5PA25%QL 22.4/365dNot coveredNot coveredNot coveredNot coveredNot coveredTier 5PA25%QL 2.4/28dTier 5PA33%QL 2.4/28d
Hyrimozadalimumab-adazNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot covered
Cyltezoadalimumab-adbmNot coveredTier 5PA25%QL 4/28dTier 5PA25%QL 4/28dNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot covered
Simlandiadalimumab-ryvkNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredTier 5PA25%QL 3/28dTier 5PA33%QL 3/28d
Yuflymaadalimumab-aatyNot coveredTier 5PA25%QL 2/28dTier 5PA25%QL 2/28dNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot covered
Amjevitaadalimumab-attoNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot covered
EnbreletanerceptTier 5PA25%QL 8/28dTier 5PA25%QL 8/28dTier 5PA25%QL 8/28dTier 5PA25%QL 8/28dTier 5PA25%QL 8/28dTier 5PA26%QL 8/28dTier 5PA25%QL 4/28dTier 5PA25%QL 8/28dTier 5PA31%QL 4/28dTier 5PA33%QL 8/28dTier 5PA25%QL 4.08/28dTier 5PA33%QL 4.08/28d
Cimziacertolizumab pegolNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot covered
SimponigolimumabNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot covered

Where a plan covers several strengths or forms of a drug, the cell shows the least restricted one. Costs are the 30-day preferred-pharmacy cost-sharing in the initial coverage phase, from the CMS 2026 formulary files. Click a plan for its full drug list.